A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma
Clinical trial NCT06650514 · RECRUITING
Trial details
- NCT number
- NCT06650514
- Sponsor
- Vall d'Hebron Institute of Oncology
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-27
- Primary completion
- 2026-06-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.